Research / ANG-PD / Fundamental state Inspectable configuration
State dimensions Filing 0001039828-24-000071 Insurance
Cash 100th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.cash
$13.5B · CORE · VALID
Premium growth 0th Own-history percentile · N=20
Evidence method Yoy · gp.insurance.premiums
-84.53% · CORE · VALID
Revenue growth 70th Own-history percentile · N=20
Evidence method Yoy · gp.fundamentals.revenue
49.42% · CORE · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 51 states Self-history eligible
Sep 30, 2021 4/4 normalized Level 3 Dec 31, 2021 4/4 normalized Level 3 Mar 31, 2022 4/4 normalized Level 3 Jun 30, 2022 3/3 normalized Level 3 Sep 30, 2022 4/4 normalized Level 3 Dec 31, 2022 4/4 normalized Level 3 Mar 31, 2023 4/4 normalized Level 3 Jun 30, 2023 4/4 normalized Level 3 Sep 30, 2023 4/4 normalized Level 3 Dec 31, 2023 4/4 normalized Level 3 Mar 31, 2024 3/3 normalized Level 3 Jun 30, 2024 4/5 normalized Level 3 Sep 30, 2024 4/5 normalized Level 3 Dec 31, 2024 4/5 normalized Level 3 Mar 31, 2025 4/5 normalized Level 3 Jun 30, 2025 5/6 normalized Level 3 Sep 30, 2025 4/5 normalized Level 3 Dec 31, 2025 5/6 normalized Level 3 Mar 31, 2026 4/5 normalized Level 3 Jun 30, 2026 6/6 normalized Level 4 Period transition
What moved in the state? Cash Increased
Previous $9.8B
Current $13.5B
Delta $3.7B Premium Growth Decreased
Previous -39.37%
Current -84.53%
Delta -45.16% Revenue Growth Decreased
Previous 100.35%
Current 49.42%
Delta -50.93% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.